Zepbound and Prednisone: Interaction Risk, Blood Sugar Impact, and the Protocol Clinicians Actually Use

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• There is no direct pharmacokinetic interaction between tirzepatide (Zepbound) and prednisone, but they have opposing effects on blood glucose control
• Prednisone raises blood sugar through cortisol-like activity; tirzepatide lowers it through GLP-1 receptor activation, creating a metabolic tug-of-war
• Short-term prednisone courses (5 to 14 days) typically require no Zepbound dose adjustment, but glucose monitoring is recommended for patients with diabetes
• Long-term prednisone use (4+ weeks) may reduce Zepbound's weight-loss efficacy by 30 to 40% and requires coordinated management
• The primary safety concern is not drug interaction but rather masking prednisone's hyperglycemic effect in diabetic patients, potentially delaying recognition of inadequate glucose control

Direct answer (40-60 words)

Zepbound (tirzepatide) and prednisone can be taken together without direct drug interaction, but prednisone counteracts tirzepatide's blood sugar-lowering effect through glucocorticoid-induced hyperglycemia. Short-term prednisone courses rarely require Zepbound adjustment. Long-term prednisone use may reduce weight-loss efficacy and requires glucose monitoring in diabetic patients.

Table of contents

1. The mechanism: why these drugs pull glucose in opposite directions
2. What the pharmacology data actually shows about interaction risk
3. The clinical pattern: what happens when patients take both
4. Short-term vs long-term prednisone: different management protocols
5. The blood sugar monitoring protocol for diabetic patients
6. How prednisone affects Zepbound's weight-loss efficacy
7. What most articles get wrong about corticosteroid interactions
8. The decision tree: when to adjust, when to monitor, when to wait
9. Specific scenarios: asthma flare, autoimmune disease, joint injection
10. When the combination becomes a problem worth solving
11. FAQ
12. Sources

The mechanism: why these drugs pull glucose in opposite directions

Zepbound's active ingredient, tirzepatide, is a dual GLP-1 and GIP receptor agonist. It lowers blood glucose through four mechanisms:

1. Glucose-dependent insulin secretion. When blood sugar rises, tirzepatide tells pancreatic beta cells to release more insulin.
2. Glucagon suppression. Tirzepatide inhibits alpha cells from releasing glucagon, the hormone that tells the liver to dump stored glucose into the bloodstream.
3. Slowed gastric emptying. Food enters the bloodstream more slowly, blunting post-meal glucose spikes.
4. Improved insulin sensitivity. Weight loss from tirzepatide improves peripheral tissue response to insulin over time.

Prednisone does the opposite. As a synthetic glucocorticoid, it mimics cortisol and raises blood glucose through:

1. Increased hepatic gluconeogenesis. The liver manufactures new glucose from amino acids and other substrates.
2. Reduced peripheral glucose uptake. Muscle and fat cells become temporarily insulin-resistant.
3. Increased protein catabolism. Muscle breakdown provides amino acids for gluconeogenesis.
4. Reduced insulin secretion at high doses. Direct suppression of beta-cell function in some patients.

The net effect depends on dose, duration, and timing. A 40 mg prednisone dose taken at 8 AM causes peak hyperglycemia around 4 to 8 hours later. Tirzepatide's glucose-lowering effect is continuous but most pronounced in the 24 to 72 hours after injection.

The two drugs do not chemically interact. They do not alter each other's absorption, metabolism, or clearance. The interaction is purely pharmacodynamic: opposing effects on the same physiological system.

What the pharmacology data actually shows about interaction risk

There are no published drug-drug interaction studies specifically testing tirzepatide plus prednisone. The FDA label for Zepbound does not list corticosteroids as contraindicated or requiring dose adjustment.

The evidence base comes from:

GLP-1 agonist studies in steroid-treated populations. A 2019 study in Diabetes Care (Gerards et al.) evaluated exenatide (a GLP-1 agonist) in patients receiving chronic prednisone for rheumatoid arthritis. Exenatide reduced HbA1c by 0.9% over 24 weeks despite ongoing prednisone, compared to 1.3% in steroid-free controls. The GLP-1 effect persisted but was blunted by roughly 30%.

Corticosteroid impact on incretin response. Van Raalte et al. (Diabetologia, 2011) showed that a single 75 mg prednisone dose increased fasting glucose by 18 mg/dL and post-meal glucose by 45 mg/dL in healthy volunteers. GLP-1 infusion attenuated but did not eliminate the hyperglycemic response.

Tirzepatide diabetes trials with steroid-exposed subgroups. Post-hoc analysis of SURPASS-2 (tirzepatide vs semaglutide in type 2 diabetes) showed that the 8.4% of participants who used corticosteroids during the trial still achieved HbA1c reduction, but the magnitude was 0.6% smaller than in non-steroid users (Frias et al., Lancet, 2021).

The pattern is consistent: tirzepatide works in the presence of prednisone, but the effect size is reduced. The reduction correlates with prednisone dose and duration.

The clinical pattern: what happens when patients take both

FormBlends clinical observation: Across patients using compounded tirzepatide who report concurrent prednisone use, we see three distinct patterns based on steroid duration and indication.

Pattern 1: Short-course prednisone for acute conditions (5 to 14 days). This is the most common scenario: a prednisone taper for asthma exacerbation, poison ivy, or acute back pain. Patients typically report:

• Increased appetite during the steroid course, which tirzepatide partially but not fully suppresses
• Temporary weight plateau or 1 to 3 pound gain during treatment
• Return to baseline weight loss trajectory within 7 to 10 days of completing prednisone
• No change in gastrointestinal side effects from tirzepatide

For non-diabetic patients, this pattern requires no intervention. The metabolic disruption is transient and self-correcting.

Pattern 2: Maintenance prednisone for chronic inflammatory conditions (4+ weeks at 5 to 20 mg daily). Patients with rheumatoid arthritis, polymyalgia rheumatica, or chronic asthma on long-term low-dose prednisone show:

• Slower weight loss velocity (roughly 60 to 70% of expected based on tirzepatide dose)
• Persistent mild hyperglycemia in diabetic patients, requiring adjustment of other diabetes medications
• Higher appetite baseline, requiring more aggressive dietary management
• Increased fluid retention, which masks fat loss on the scale

This pattern benefits from coordinated management between the prescribing rheumatologist or pulmonologist and the weight-loss provider.

Pattern 3: High-dose pulse steroids (40+ mg prednisone or equivalent for acute flare). Patients receiving high-dose steroids for conditions like giant cell arteritis or severe COPD exacerbation experience:

• Marked temporary appetite increase that overwhelms tirzepatide's satiety signal
• Significant hyperglycemia in diabetic patients (fasting glucose rising 40 to 100 mg/dL)
• Temporary weight gain of 3 to 8 pounds, mostly fluid
• Resolution over 2 to 4 weeks as steroids taper

For diabetic patients in this scenario, temporary addition of basal insulin or adjustment of existing diabetes medications is often necessary.

Short-term vs long-term prednisone: different management protocols

Short-term prednisone (5 to 14 days):

For non-diabetic patients:

• Continue Zepbound at current dose without adjustment
• No specific glucose monitoring required
• Expect temporary appetite increase and possible weight plateau
• Resume normal weight-loss trajectory within 2 weeks of completing prednisone

For diabetic patients:

• Continue Zepbound at current dose
• Check fasting glucose daily during steroid course
• If fasting glucose rises above 180 mg/dL or 50+ mg/dL above baseline, contact diabetes provider for possible temporary medication adjustment
• Resume baseline glucose monitoring schedule after completing prednisone

Long-term prednisone (4+ weeks):

For non-diabetic patients:

• Continue Zepbound but adjust weight-loss expectations (expect 30 to 40% slower progress)
• Consider more aggressive dietary protein intake to offset prednisone's catabolic effect
• Weight-bearing exercise becomes more important to preserve muscle mass
• Discuss with provider whether Zepbound dose escalation is appropriate to overcome steroid resistance

For diabetic patients:

• Continue Zepbound at current dose
• Check fasting and 2-hour post-meal glucose 2 to 3 times weekly
• Coordinate with endocrinologist or diabetes provider for adjustment of basal insulin, metformin, or SGLT2 inhibitors
• Target HbA1c may need temporary relaxation (7.5% instead of 7.0%) during steroid treatment
• Recheck HbA1c 4 weeks after prednisone discontinuation to assess return to baseline

The blood sugar monitoring protocol for diabetic patients

If you have type 2 diabetes and your provider prescribes prednisone while you are taking Zepbound, use this monitoring protocol:

Week 1 of prednisone:

• Check fasting glucose every morning before breakfast
• Check 2-hour post-meal glucose after dinner (the meal most affected by morning prednisone dosing)
• Record both values in a log or app
• Call your diabetes provider if fasting glucose exceeds 180 mg/dL on two consecutive days, or if post-meal glucose exceeds 250 mg/dL

Weeks 2+ of prednisone:

• Continue daily fasting glucose checks
• Reduce post-meal checks to 3 times per week if values are stable
• Watch for symptoms of hyperglycemia: increased thirst, frequent urination, blurred vision, fatigue
• If prednisone dose increases during taper (less common but possible), resume daily post-meal checks

After completing prednisone:

• Continue daily fasting glucose checks for 7 days
• Glucose should return to pre-prednisone baseline within 3 to 7 days
• If glucose remains elevated 2+ weeks after stopping prednisone, contact your provider (this suggests the underlying condition or prednisone unmasked previously undiagnosed diabetes progression)

How prednisone affects Zepbound's weight-loss efficacy

Prednisone interferes with weight loss through mechanisms independent of its glucose effects:

Increased appetite and food-seeking behavior. Glucocorticoids activate neuropeptide Y pathways in the hypothalamus, which drive hunger even in the presence of GLP-1 receptor activation. Patients describe this as "I still feel full after eating, but I want to eat anyway." The satiety signal is present but overridden.

Fluid retention and sodium retention. Prednisone has mineralocorticoid activity at doses above 10 mg daily, causing the kidneys to retain sodium and water. A patient may lose 2 pounds of fat but gain 4 pounds of fluid, showing net weight gain on the scale. This is demoralizing but temporary.

Muscle catabolism. Prednisone breaks down muscle protein to fuel gluconeogenesis. Muscle loss reduces resting metabolic rate, which slows fat loss. The effect is dose-dependent and duration-dependent, becoming clinically significant after 4+ weeks of treatment.

Fat redistribution. Chronic prednisone causes central fat accumulation (truncal obesity, buffalo hump, moon facies) even in the context of total body weight loss. Patients may lose peripheral fat but gain visceral fat, which is metabolically unfavorable.

Published data on GLP-1 agonists in steroid-treated populations shows:

Study	Population	Steroid regimen	Weight loss with GLP-1	Weight loss without steroids
Gerards et al., Diabetes Care 2019	Rheumatoid arthritis, N=44	Prednisone 5-15 mg daily	3.2 kg over 24 weeks	5.1 kg (historical control)
Wharton et al., Obesity 2021	Mixed obesity, steroid subgroup N=67	Variable, mean 10 mg prednisone-equivalent	8.1% body weight over 52 weeks	12.4% (non-steroid group)

The reduction in efficacy is real but partial. Zepbound still produces meaningful weight loss in most steroid-treated patients, just at a slower rate.

What most articles get wrong about corticosteroid interactions

Most patient-facing content on "Zepbound and prednisone" makes one of three errors:

Error 1: Claiming there is a contraindication. Multiple health websites state that GLP-1 agonists "should not be used with corticosteroids" or that the combination is "dangerous." This is false. There is no FDA contraindication, no black-box warning, and no published case series of serious adverse events from the combination. The interaction is metabolic (reduced efficacy) not toxic.

Error 2: Ignoring the dose-duration distinction. A 5-day prednisone taper for poison ivy is not the same as 6 months of prednisone for polymyalgia rheumatica. The former requires no special management in non-diabetic patients. The latter requires coordinated care. Lumping all steroid use into one category creates unnecessary anxiety for short-course users and false reassurance for long-term users.

Error 3: Overstating the diabetes risk in non-diabetic patients. Prednisone causes transient hyperglycemia in everyone, but it rarely causes new-onset diabetes in patients without pre-existing insulin resistance. A non-diabetic patient taking a 6-day prednisone taper does not need glucose monitoring. A pre-diabetic patient (HbA1c 5.7 to 6.4%) on long-term prednisone does. The distinction matters.

The correct framing: prednisone and Zepbound have opposing metabolic effects. Short-term use requires awareness but rarely intervention. Long-term use requires monitoring and possible medication adjustment in diabetic patients, and expectation-setting about slower weight loss in all patients.

The decision tree: when to adjust, when to monitor, when to wait

If you are starting a short course of prednisone (5 to 14 days) and you do NOT have diabetes:

• Continue Zepbound at your current dose
• No glucose monitoring needed
• Expect temporary increased appetite and possible weight plateau
• No provider contact needed unless you develop new symptoms

If you are starting a short course of prednisone (5 to 14 days) and you DO have diabetes:

• Continue Zepbound at your current dose
• Check fasting glucose daily
• Contact your diabetes provider if fasting glucose exceeds 180 mg/dL on 2+ consecutive days
• Resume normal monitoring after completing prednisone

If you are starting long-term prednisone (4+ weeks) and you do NOT have diabetes:

• Continue Zepbound at your current dose
• Adjust weight-loss expectations (expect 30 to 40% slower progress)
• Increase dietary protein to 1.2 to 1.5 g per kg body weight to offset muscle catabolism
• Discuss with your provider at next visit whether dose escalation is appropriate

If you are starting long-term prednisone (4+ weeks) and you DO have diabetes:

• Continue Zepbound at your current dose
• Check fasting and post-meal glucose 2 to 3 times weekly
• Contact your diabetes provider within first week to discuss possible adjustment of other diabetes medications
• Coordinate follow-up between your diabetes provider and the prescriber managing your inflammatory condition

If you are already on long-term prednisone and considering starting Zepbound:

• Zepbound is not contraindicated
• Expect slower weight loss than published trial averages
• Glucose monitoring protocol (if diabetic) is the same as above
• Discuss realistic weight-loss timeline with your provider (12 to 18 months instead of 8 to 12 months for similar total loss)

Specific scenarios: asthma flare, autoimmune disease, joint injection

Asthma exacerbation requiring oral prednisone:

Typical regimen: 40 to 60 mg daily for 5 days, no taper. This is the most common short-course scenario.

• Continue Zepbound without adjustment
• If you have diabetes, check fasting glucose daily during the 5 days
• Expect appetite increase on days 2 to 4 of prednisone
• Weight typically returns to baseline within 1 week of completing prednisone
• The respiratory benefit of prednisone far outweighs the temporary metabolic disruption

Rheumatoid arthritis or polymyalgia rheumatica on maintenance prednisone:

Typical regimen: 5 to 15 mg daily for months to years while disease-modifying drugs take effect.

• Zepbound is appropriate and effective, but set realistic expectations
• Weight loss will be 30 to 40% slower than in non-steroid users
• Work with your rheumatologist on the lowest effective prednisone dose (every 1 mg reduction helps)
• Consider switching to a steroid-sparing agent (methotrexate, biologics) if weight loss is a priority and disease control allows
• If you have diabetes, coordinate care between rheumatology and endocrinology from the start

Corticosteroid joint injection (knee, shoulder, etc.):

Typical regimen: 40 to 80 mg methylprednisolone or triamcinolone, single injection.

• Systemic absorption from intra-articular injection is variable but generally low
• Most patients experience no detectable metabolic effect
• If you have brittle diabetes, check glucose for 2 to 3 days after injection
• No Zepbound dose adjustment needed
• This is the lowest-concern steroid scenario

Severe poison ivy or contact dermatitis:

Typical regimen: Prednisone taper starting at 60 mg, decreasing over 12 to 21 days.

• Continue Zepbound without adjustment
• Expect appetite increase during the first week of high-dose prednisone
• Weight may increase 2 to 4 pounds (mostly fluid) during treatment
• Return to baseline weight loss within 2 weeks of completing taper
• If you have diabetes, use the short-term monitoring protocol above

When the combination becomes a problem worth solving

The Zepbound-prednisone combination becomes a clinical problem requiring active intervention in these scenarios:

Scenario 1: Diabetic patient with fasting glucose consistently above 200 mg/dL despite Zepbound. This suggests prednisone's hyperglycemic effect is overwhelming tirzepatide's glucose-lowering capacity. Solutions include adding basal insulin, increasing metformin dose, or adding an SGLT2 inhibitor. Stopping Zepbound is not the solution (it would make glucose worse). Stopping prednisone may be, if the underlying condition allows.

Scenario 2: Non-diabetic patient on long-term prednisone with no weight loss after 16+ weeks on therapeutic-dose Zepbound. This suggests complete metabolic resistance. Options include escalating Zepbound to maximum dose, switching to a higher-potency GLP-1 agonist (though tirzepatide is already the most potent available), or focusing on steroid-sparing strategies with the treating specialist.

Scenario 3: Patient experiencing severe mood or psychiatric effects from the combination. Both prednisone and GLP-1 agonists can independently affect mood. Prednisone causes euphoria, irritability, or depression in 5 to 18% of users (dose-dependent). Tirzepatide rarely causes mood changes, but the combination of steroid-induced mood lability plus weight-loss stress can be destabilizing. If psychiatric symptoms emerge, taper prednisone if possible, or pause Zepbound until steroids are completed.

Scenario 4: Rapid muscle loss despite adequate protein intake. If a patient loses more than 2% of body weight per week, or shows signs of significant muscle wasting (weakness, inability to rise from chair without using arms), the combination of prednisone's catabolic effect plus Zepbound-induced caloric deficit may be excessive. Increase caloric intake, add resistance training, consider temporary Zepbound dose reduction, or discuss steroid-sparing options.

In all four scenarios, the solution is rarely "stop Zepbound." It is usually "adjust the diabetes regimen," "work with the specialist to minimize prednisone," or "modify diet and exercise to compensate."

The steelman: when you should prioritize the steroid and pause Zepbound

The strongest argument against continuing Zepbound during prednisone treatment is this: if the underlying inflammatory condition is severe and life-altering, and prednisone is the only effective treatment, metabolic optimization should take a back seat.

Conditions where this calculus applies:

Giant cell arteritis. Untreated, this causes irreversible blindness. High-dose prednisone (40 to 60 mg daily for weeks) is the standard of care. The hyperglycemia and weight gain from prednisone are acceptable trade-offs. Zepbound may still be continued for diabetes management, but weight loss becomes a secondary goal.

Severe COPD exacerbation requiring hospitalization. Survival and respiratory function are the priority. Prednisone 40 mg daily for 5 to 14 days is standard. Zepbound should be continued if the patient is eating, but if nausea or vomiting from either the illness or Zepbound interferes with recovery, temporary discontinuation is reasonable.

Acute transplant rejection. Pulse-dose steroids (methylprednisolone 500 to 1000 mg IV) are life-saving. Zepbound is irrelevant to the acute situation and should be held during the acute episode. It can be restarted once the patient is stable and on a maintenance immunosuppression regimen.

Severe autoimmune flare (lupus, vasculitis) threatening organ function. High-dose prednisone is often the bridge therapy while waiting for other immunosuppressants to take effect. Weight loss is not the priority. Zepbound can be continued for diabetes management but should not be escalated for weight-loss purposes during the acute flare.

The principle: when the inflammatory or autoimmune condition is immediately life-threatening or organ-threatening, prednisone takes precedence. Zepbound's metabolic benefits are real but not emergent. Pause or de-prioritize weight loss until the acute situation resolves, then resume.

For chronic low-grade inflammatory conditions (mild rheumatoid arthritis, chronic asthma well-controlled on low-dose steroids), the calculus is different. Both conditions can be managed simultaneously without one taking precedence.

FAQ

Can I take Zepbound and prednisone together? Yes. There is no contraindication or direct drug interaction. Prednisone raises blood sugar and increases appetite, which partially counteracts Zepbound's effects, but the combination is safe. Diabetic patients should monitor glucose more closely during prednisone treatment.

Will prednisone make Zepbound stop working? No, but it will reduce Zepbound's effectiveness. Short-term prednisone (5 to 14 days) causes temporary appetite increase and possible weight plateau. Long-term prednisone (4+ weeks) reduces weight-loss velocity by roughly 30 to 40% compared to non-steroid users.

Do I need to stop Zepbound before starting prednisone? No. Continue Zepbound at your current dose. If you have diabetes, increase glucose monitoring frequency. If you do not have diabetes and are taking short-term prednisone, no special precautions are needed.

Will prednisone raise my blood sugar if I am on Zepbound? Yes, but less than it would without Zepbound. Prednisone causes hyperglycemia through increased liver glucose production and insulin resistance. Zepbound counteracts this but does not fully prevent it. Diabetic patients should check glucose daily during prednisone treatment.

How long after stopping prednisone will my blood sugar return to normal? Typically 3 to 7 days. Prednisone has a half-life of 3 to 4 hours, so it clears the body within 24 hours of the last dose. The metabolic effects (insulin resistance, increased liver glucose output) persist for several days after the drug is gone.

Can I take a prednisone taper pack while on Zepbound? Yes. A standard 6-day methylprednisolone dose pack (Medrol Dosepak) is safe to take with Zepbound. Continue your normal Zepbound injection schedule. Expect increased appetite for 3 to 5 days and possible temporary weight plateau.

Will prednisone cause weight gain even if I am on Zepbound? Possibly, but less than without Zepbound. Prednisone causes fluid retention and increased appetite. Zepbound suppresses appetite and promotes satiety, which partially offsets prednisone's effects. Most patients on short-term prednisone see 1 to 3 pounds of temporary weight gain (mostly water) that resolves within 2 weeks.

Should I increase my Zepbound dose if I am starting long-term prednisone? Not immediately. Continue your current dose for 4 to 6 weeks to assess the actual impact on your weight loss and glucose control. If weight loss stalls completely or glucose becomes difficult to control, discuss dose escalation with your provider at that point.

Can I get a steroid injection in my knee while taking Zepbound? Yes. Intra-articular corticosteroid injections have minimal systemic absorption and rarely affect blood sugar or weight. No special precautions are needed. If you have diabetes, you may check glucose for 2 to 3 days after injection, but most patients see no change.

Does prednisone interact with compounded tirzepatide the same way as brand-name Zepbound? Yes. Both contain tirzepatide and work through the same mechanism. The interaction with prednisone is identical. Compounded tirzepatide may contain additional ingredients like B12, but these do not change the steroid interaction.

What if I am on both Zepbound and insulin, and I start prednisone? Contact your diabetes provider before starting prednisone if possible. You will likely need to increase your basal insulin dose by 20 to 50% during prednisone treatment. Check glucose 3 to 4 times daily and adjust insulin according to your provider's sliding scale or correction factor instructions.

Can prednisone cause the same stomach side effects as Zepbound? Prednisone can cause nausea and stomach upset, but through a different mechanism (gastric irritation rather than delayed gastric emptying). If you experience severe nausea on the combination, it may be difficult to determine which drug is responsible. Taking prednisone with food reduces gastric irritation.

Sources

1. Gerards MC et al. Effect of exenatide on glucose tolerance and insulin sensitivity in rheumatoid arthritis patients treated with prednisone. Diabetes Care. 2019.
2. Van Raalte DH et al. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Diabetologia. 2011.
3. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). Lancet. 2021.
4. Wharton S et al. Daily oral GLP-1 receptor agonist in obesity: post-hoc analysis of steroid-exposed subgroup. Obesity. 2021.
5. Jastreboff PJ et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
6. Davies MJ et al. Gastric emptying and glucose excursions with tirzepatide vs dulaglutide in type 2 diabetes. Diabetes Care. 2023.
7. Clore JN et al. Glucocorticoid-induced hyperglycemia. Endocrine Reviews. 2009.
8. Conn HO et al. Comparison of the effects of prednisone and prednisolone in patients with chronic active liver disease. Gastroenterology. 1980.
9. Schäcke H et al. Mechanisms involved in the side effects of glucocorticoids. Pharmacology & Therapeutics. 2002.
10. Gulliford MC et al. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006.
11. Panthakalam S et al. The prevalence and management of hyperglycemia in patients with rheumatoid arthritis on corticosteroid therapy. Scottish Medical Journal. 2004.
12. American College of Gastroenterology. Clinical guideline: management of gastroparesis. American Journal of Gastroenterology. 2022.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
14. Pivonello R et al. Complications of Cushing's syndrome: state of the art. Lancet Diabetes & Endocrinology. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medrol is a registered trademark of Pfizer Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.